Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins

Pharmacogenomics

Volumn 13, Issue 2, 2012, Pages 171-178

  Khrunin, Andrey ^a   Ivanova, Feodosia ^b   Moisseev, Alexey ^c   Khokhrin, Denis ^a   Sleptsova, Yuliya ^a,d   Gorbunova, Vera ^c   Limborska, Svetlana ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Russian Federation)

^b Yakutsk Republic Cancer Clinic   (Russian Federation)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^d PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

chemotherapy; cisplatin; DNA polymorphism; ethnic diversity; ovarian cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; GLUTATHIONE TRANSFERASE P1;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYP2E1 GENE; DNA POLYMORPHISM; DNA SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENE LOCUS; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; GSTT1 GENE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PHARMACOGENOMICS; PROGRESSION FREE SURVIVAL; RUSSIAN; THROMBOCYTOPENIA; TUMOR GENE; VOMITING; YAKUT;

ASIAN CONTINENTAL ANCESTRY GROUP; CISPLATIN; CYTOCHROME P-450 CYP2E1; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GLUTATHIONE S-TRANSFERASE PI; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; RUSSIA;

EID: 84855968767     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.140     Document Type: Article

References (54)

1. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin. Cancer Res. 15(15), 4806-4814 (2009).
2. Morris AM, Rhoads KF, Stain SC, Birkmeyer JD. Understanding racial disparities in cancer treatment and outcomes. J. Am. Coll. Surg. 211(1), 105-113 (2010).
3. Tishkoff SA, Verrelli BC. Patterns of human genetic diversity: implications for human evolutionary history and disease. Annu. Rev. Genomic Hum. Genet. 4, 293-340 (2003). (Pubitemid 37392927)
4. Kidd KK, Pakstis AJ, Speed WC, Kidd JR. Understanding human DNA sequence variation. J. Hered. 95(5), 406-420 (2004). (Pubitemid 39304777)
5. Auton A, Bryc K, Boyko AR et al. Global distribution of genomic diversity underscores rich complex history of continental human populations. Genome Res. 19(5), 795-803 (2009).
6. Coop G, Pickrell JK, Novembre J et al. The role of geography in human adaptation. PLoS Genet. 5(6), e1000500 (2009).
7. Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin. Drug Metab. Toxicol. 5(3), 243-257 (2009).
8. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol. Oncol. 112(1), 275-281 (2009).
9. Shimoyama S. Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment. J. Gastroenterol. Hepatol. 24(6), 970-981 (2009).
10. Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol. 279(21), 3540-3546 (2009).
11. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 10(1), 54-61 (2010).
12. Milligan BG. Total DNA isolation. In: Molecular Genetic Analysis of Populations. Hoelzel AR (Ed.). Oxford University Press, Oxford, UK, 29-60 (1998).
13. Coles BF, Morel F, Rauch C et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 11(8), 663-669 (2001). (Pubitemid 33078235)
14. Khrunin AV, Khokhrin DV, Limborska SA. Glutathione-S-transferase gene polymorphism in Russian populations of European part of Russia. Genetika 44(10), 1429-1434 (2008).
15. Loktionov A, Watson MA, Gunter M, Stebbings WS, Speakman CT, Bingham SA. Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis 22(7), 1053-1060 (2001). (Pubitemid 32633604)
16. Tetlow N, Robinson A, Mantle T, Board P. Polymorphism of human mu class glutathione transferases. Pharmacogenetics 14(6), 359-368 (2004). (Pubitemid 38813690)
17. Ishii T, Matsuse T, Teramoto S et al. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax 54(8), 693-696 (1999). (Pubitemid 29341405)
18. Saarikoski ST, Voho A, Reinikainen M et al. Combined effect of polymorphic gst genes on individual susceptibility to lung cancer. Int. J. Cancer 77(7), 516-521 (1998). (Pubitemid 28340896)
19. Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10(15), 4939-4943 (2004). (Pubitemid 39099767)
20. Matullo G, Palli D, Peluso M et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22(9), 1437-1445 (2001). (Pubitemid 32898701)
21. Tuimala J, Szekely G, Gundy S, Hirvonen A, Norppa H. Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis 23(6), 1003-1008 (2002). (Pubitemid 34752956)
22. Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood. 100(10), 3761-3766 (2002). (Pubitemid 35303949)
23. Sjalander A, Birgander R, Kivela A, Beckman G (1995) p53 polymorphisms and haplotypes in different ethnic groups. Hum. Hered. 45(3), 144-149 (1995).
24. Fritsche E, Gary S. Pittman, Douglas A. Bell. Localization, sequence analysis, and ethnic distribution of a 96-bp insertion in the promoter of the human CYP2E1 gene. Mutat. Res. 432(1-2), 1-5 (2000). (Pubitemid 30151203)
25. Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol. Pathol. 53(2), 88-93 (2000). (Pubitemid 30183082)
26. Ardizzoni A, Boni L, Tiseo M et al.: Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl Cancer Inst. 99(11), 847-57 (2007).
27. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol. Rep. 10(6), 1663-1682 (2003).
28. Ishimoto TM, Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 12(7), 543-553 (2002). (Pubitemid 35177084)
29. Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol. Cancer Ther. 7(10), 3247-3255 (2008).
30. Yu JJ, Lee KB, Mu C et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol. 16(3), 555-560 (2000).
31. Chen P, Wiencke J, Aldape K et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomarkers. Prev. 9(8), 843-847 (2000). (Pubitemid 30660059)
32. Au WW, Salama SA, Sierra-Torres SH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ. Health. Perspect. 111(15), 1843-1850 (2003). (Pubitemid 37526965)
33. Wolfe KJ, Wickliffe JK, Hill CE, Paolini M, Ammenheuser MM, Abdel-Rahman SZ. Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet. Genomics. 17(11), 897-905 (2007). (Pubitemid 350293790)
34. Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem. Rev. 107(5), 1387-1407 (2007). (Pubitemid 46864967)
35. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47), 7265-7279 (2003).
36. Sullivan A, Syed N, Gasco M et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23(19), 3328-3337 (2004). (Pubitemid 38669822)
37. Boige V, Mendiboure J, Pignon JP et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-2005. J. Clin. Oncol. 28(15), 2556-2564 (2010).
38. Kweekel DM, Gelderblom H, Antonini NF et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur. J. Cancer 45(4), 572-578 (2009).
39. Huang MY, Huang ML, Chen MJ et al. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet. Genomics 21(1), 18-25 (2011).
40. Ryu JS, Hong YC, Han HS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44(3), 311-316 (2004).
41. Zhou C, Ren S, Zhou S et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J. Clin. Oncol. 40(10), 954-960 (2010).
42. Tibaldi C, Giovannetti E, Vasile E S et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin- treated advanced non-small cell lung cancer patients. Clin. Cancer. Res. 14(6), 1797-1803 (2008). (Pubitemid 351469466)
43. Kim HS, Kim MK, Chung HH et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol. Oncol. 113(2), 264-269 (2009).
44. Smith S, Su D, Rigault de la Longrais IA et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J. Clin. Oncol. 25(33), 5172-5179 (2007). (Pubitemid 350232247)
45. Nagle CM, Chenevix-Trench G, Spurdle AB, Webb PM. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur. J. Cancer 43(2), 283-290 (2007). (Pubitemid 46123985)
46. Lee JM, Wu MT, Lee YC et al. Association of GSTP1 polymorphism and survival for esophageal cancer. Clin. Cancer. Res. 11(13), 4749-4753 (2005).
47. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol. 25(29), 4528-4535 (2007). (Pubitemid 350035308)
48. Kim JG, Sohn SK, Chae YS et al. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother. Pharmacol. 64(2), 355-360 (2009).
49. Gadducci A, Di Cristofano C, Zavaglia M et al. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel-plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res. 26(1B), 687-693 (2006). (Pubitemid 43206035)
50. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25(11), 1639-1648 (2006).
51. Liu H, Baliga M, Baliga R. Effect of cytochrome P450 2E1 inhibitors on cisplatin-induced cytotoxicity to renal proximal tubular epithelial cells. Anticancer Res. 22(2A), 863-868 (2002). (Pubitemid 34475241)
52. Liu H, Baliga R. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 63(5), 1687-1696 (2003). (Pubitemid 36513314)
53. Lu Y, Cederbaum AI. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol. Sci. 89(2), 515-523 (2006). (Pubitemid 43126011)
54. Uchimoto T, Itoga S, Nezu M, Sunaga M, Tomonaga T, Nomura F. Role of the genetic polymorphisms in the 5́-flanking region for transcriptional regulation of the human CYP2E1 gene. Alcohol. Clin. Exp. Res. 31(1 Suppl.), S36-S42 (2007).